Dr. Priya Nandakumar brings scientific and clinical insight to The Catalyst Brief’s coverage of biomedical research and healthcare innovation. Her work bridges experimental findings, clinical data, and industry strategy, helping readers interpret what new evidence means beyond the lab or trial setting. At The Catalyst Brief, Priya emphasizes translational relevance and long-term implications for patients and pipelines.
160 articlesMostly Regulatory & Policy and Biopharmaceutical Industry
Regulatory & PolicyThe U.S. Food and Drug Administration’s newly released guidance on Bayesian methods signals a pivotal change in how clinical trials for cancers and rare diseases may be conducted. This shift could foster more efficient research, lower development costs, and drive faster medical innovation across the biopharmaceutical sector.
Dr. Priya NandakumarJun 16, 2026
AI in Drug DiscoveryVerge Labs has introduced a new artificial intelligence model that addresses patient stratification challenges in neurology clinical trials—a notoriously difficult area for drug development. This in-depth analysis explores what makes the model unique, the problems it aims to solve, and wider consequences for precision medicine, trial optimization, and pharmaceutical innovation.
Dr. Priya NandakumarJun 16, 2026
Biotech InnovationWith obesity rates continuing to surge globally and demand for novel therapies reaching record highs, the pharmaceutical industry is investing heavily in new classes of obesity drugs—particularly peptides and other innovative compounds. This in-depth analysis covers the latest developments in the obesity drug pipeline, explores how peptide-based medicines are moving into the mainstream, examines scientific and regulatory challenges, and clarifies the wider context for patients, providers, and industry stakeholders.
Dr. Priya NandakumarJun 12, 2026
Medical TechnologyEgg freezing has become more visible as a reproductive option over the past decade, yet it continues to be shaped by substantial obstacles. This analysis explores the lingering challenges associated with egg freezing—high expenses, variable success rates, and the crucial role of timing—while also highlighting how healthcare providers are striving to lower these barriers, enhance patient outcomes, and expand access to fertility preservation.
Dr. Priya NandakumarJun 8, 2026
Biotech InnovationPresented at the American Diabetes Association conference, Eli Lilly’s retatrutide continues to show promise as a next-generation obesity therapy, highlighting advancements in efficacy and patient safety. The new data provide critical insights into how this triple agonist could shape future obesity management.
Dr. Priya NandakumarJun 6, 2026
Regulatory & PolicyIn a pivotal ruling for the pharmaceutical industry, the Supreme Court determined that Hikma Pharmaceutical did not violate Amarin's patents through its use of skinny labeling—a practice that involves omitting certain patented uses on generic drug labels. This verdict may reshape how patent litigation unfolds in the generic drug sector.
Dr. Priya NandakumarJun 4, 2026
Healthcare InvestmentThe considerable funding raised by NewLimit underscores growing investor confidence in longevity therapeutics. The company is gearing up for a clinical trial that could pave the way for novel approaches to treating age-related liver diseases.
Dr. Priya NandakumarJun 2, 2026
Biopharmaceutical IndustryIn a significant move within the biopharmaceutical sector, Servier is set to expand its neuromuscular disease portfolio by purchasing a promising candidate drug from Edgewise Therapeutics. This acquisition reflects growing investment interests in therapies tackling muscular dystrophy, a debilitating group of genetic disorders.
Dr. Priya NandakumarJun 1, 2026
Regulatory & PolicyThe proposed overhaul targets the core regulatory framework for all federal grants, prompting alarm among researchers who fear political factors may outweigh scientific merit. This analysis explores the potential impacts and implications of this significant policy shift.
Dr. Priya NandakumarMay 29, 2026
Regulatory & PolicyThe legal action alleges that UnitedHealthcare engaged in 'upcoding' where the severity of members' health statuses was exaggerated to secure additional Medicaid reimbursement. This raises pivotal questions about oversight in Medicaid managed care plans serving elderly populations.
Dr. Priya NandakumarMay 29, 2026
Regulatory & PolicyIn response to new FDA wellness guidance, a flood of wearable devices with unvalidated blood pressure measurement technology has entered the consumer market, raising concerns about accuracy and safety. This development underscores the complex balance regulators face in fostering innovation while ensuring public health.
Dr. Priya NandakumarMay 28, 2026
Biopharmaceutical IndustryTriple negative breast cancer (TNBC) continues to pose significant treatment challenges due to its aggressive nature and limited targeted therapies. The FDA approval of Datroway, an antibody drug conjugate developed by AstraZeneca and Daiichi Sankyo, introduces a new therapeutic option aiming to improve patient outcomes in this difficult-to-treat population.
Dr. Priya NandakumarMay 25, 2026